Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPB-101 in Platinum-resistant Ovarian Cancer
NCT07030907Phase 1Terminated
- Sponsor
- Outpace Bio
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OPB-101 in ovarian cancer, sponsored by Outpace Bio. Primary endpoint: Safety at 2 years. Started Jun 2025; status: terminated.
02
Drugs
OPB-101
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07030907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030907.